Changes in Commercial Insurance Coverage for GIP and GLP-1 Agonists

(Please use a modern browser to see the interactive version of this visualization)

Data reflect share of commercial and health exchange covered lives across all available forms and dosages of each medication. Restricted coverage means insurance coverage requires prior authorization or step therapy. Data for 2024 is as of November 2024. Data for 2025 is as of August 2025. Data for 2026 is as of January 2026. Ozempic, Mounjaro, Victoza, and liraglutide are prescribed for Type 2 diabetes. Wegovy, Zepbound, and Saxenda are prescribed for weight loss.